Dr. Lal PathLabs (DLPL), one of India’s most trusted diagnostic networks, has launched the country’s first dedicated Complement Testing Laboratory, further strengthening its leadership in autoimmune and immunology diagnostics. With this facility, several internationally recognised complement tests are now accessible to Indian patients for the first time—enabling earlier, more accurate diagnosis of complex immune-mediated and kidney-related disorders.
Across India, autoimmune and inflammatory diseases are being identified more frequently, yet many patients still experience long delays before receiving a clear diagnosis. Symptoms such as fever, fatigue, joint pain, swelling, or kidney dysfunction are often vague and overlapping, causing patients to consult multiple specialists before the underlying cause is detected. Because many autoimmune conditions progress silently, significant organ damage may occur before symptoms become obvious.
This is where complement testing becomes essential.
The complement system is a network of blood proteins that helps defend against infections, protects vital organs, and clears damaged or dead cells. When this system becomes dysfunctional, the consequences can be serious:
Underactive complement system: increases susceptibility to recurrent or severe infections, particularly in children.
Overactive complement system: can mistakenly target healthy tissues, contributing to illnesses such as lupus, C3 glomerulopathy, atypical HUS, vasculitis, rheumatoid arthritis, certain kidney diseases, transplant rejection, and even sepsis.
Complement testing measures key proteins—including C3, C4, and C5—to determine whether the immune response is weakened, overactive, or dysregulated. These insights help clinicians pinpoint the underlying cause of persistent or unexplained symptoms, leading to faster and more precise diagnosis.
The new Complement Laboratory at Dr. Lal PathLabs features advanced immunoturbidimetric and ELISA platforms and operates under stringent CAP and NABL accreditation standards. For patients facing autoimmune or inflammatory disorders, this development promises quicker clarity, better-informed treatment decisions, and a more confident approach to long-term health management.
